Anticancer Nanotherapeutics for Lung Cancer Therapy

Dear Colleagues,

Lung cancer has become one of the major types of cancers threatening the health and life of humankind, with continuously growing mortality and morbidity. The pharmaceutical sector has made many efforts to combat lung cancer, and a series of novel therapeutics have been developed. Among nanotherapeutics, those that shed light on their superior drug loading and delivery attributes are particularly noteworthy. Nanotherapeutics refer to nanosystems in which therapeutic agents are encapsulated or attached to nanoparticles, such as liposomes, polymeric micelles, and nanogels. Most importantly, they are asserted to possess enhanced targeting functions over conventional therapeutics, due to the passive or active targeting abilities. The relevant topics are hotspots in the current scientific community, which attract research interests from all over the world. 

This Special Issue aims to welcome impressive contributions (articles, reviews, communications, etc.) on anticancer nanotherapeutics for lung cancer therapy. The Guest Editor team believes that input from global scientists can contribute to the understanding of nanotherapeutics design and development, and accelerate the advancement of lung cancer treatment. Nanomedicines intended for pulmonary delivery will be especially encouraged because of the pathological nature of lung cancer, while targeting nanosystems delivered by other routes are also considered. We look forward to your contributions.

Dr. Zhengwei Huang
Dr. Xialin Dai
Dr. Yanjuan Huang
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.